330 related articles for article (PubMed ID: 26138259)
1. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
[TBL] [Abstract][Full Text] [Related]
2. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
Charytan DM; Himmelfarb J; Ikizler TA; Raj DS; Hsu JY; Landis JR; Anderson AH; Hung AM; Mehrotra R; Sharma S; Weiner DE; Williams M; DiCarli M; Skali H; Kimmel PL; Kliger AS; Dember LM;
Kidney Int; 2019 Apr; 95(4):973-982. PubMed ID: 30473139
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
4. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
5. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
8. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
9. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
Hammer F; Malzahn U; Donhauser J; Betz C; Schneider MP; Grupp C; Pollak N; Störk S; Wanner C; Krane V;
Kidney Int; 2019 Apr; 95(4):983-991. PubMed ID: 30712923
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
12. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M
Am J Kidney Dis; 2016 Oct; 68(4):591-598. PubMed ID: 27265777
[TBL] [Abstract][Full Text] [Related]
13. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
[TBL] [Abstract][Full Text] [Related]
15. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients.
Vukusich A; Kunstmann S; Varela C; Gainza D; Bravo S; Sepulveda D; Cavada G; Michea L; Marusic ET
Clin J Am Soc Nephrol; 2010 Aug; 5(8):1380-7. PubMed ID: 20522535
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone in chronic hemodialysis patients improves cardiac function.
Taheri S; Mortazavi M; Shahidi S; Pourmoghadas A; Garakyaraghi M; Seirafian S; Eshaghian A; Ghassami M
Saudi J Kidney Dis Transpl; 2009 May; 20(3):392-7. PubMed ID: 19414940
[TBL] [Abstract][Full Text] [Related]
19. Eplerenone and chronic heart failure. No comparison with spironolactone.
Prescrire Int; 2013 Jun; 22(139):148-9. PubMed ID: 23866347
[TBL] [Abstract][Full Text] [Related]
20. Eplerenone reduces morbidity and mortality after acute MI.
Cardiovasc J S Afr; 2006; 17(5):280. PubMed ID: 17117244
[No Abstract] [Full Text] [Related]
[Next] [New Search]
